Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Wide series of GH-stimulating compounds presented by Novo Nordisk

Nov. 18, 1999

Merck synthesizes novel oxytocin receptor antagonists with piperazine structure

Nov. 17, 1999

GelTex and Sankyo sign letter of intent for marketing CholestaGel and second-generation product

Nov. 17, 1999

OGS renegotiates license agreement with Searle for OGT-918

Nov. 17, 1999

Vitronectin receptor antagonists for bone disorders, etc., in development at AHP

Nov. 15, 1999

NovoRapid now on the market in the U.K.

Nov. 15, 1999

Positive findings of ACTION I study presented at ASN

Nov. 12, 1999

Insulin sensitizer improves cardiac function in diabetic mice

Nov. 11, 1999

Results of phase II trial of GA-EPO presented at ASN

Nov. 10, 1999

Nippon Zoki compound evaluated in diabetic patients with renal failure

Nov. 10, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...